nach oben

Cancer and Metastasis Reviews

Erschienen in:

27.03.2023

Oral delivery of RNAi for cancer therapy

verfasst von: Humayra Afrin, Renu Geetha Bai, Raj Kumar, Sheikh Shafin Ahmad, Sandeep K. Agarwal, Md Nurunnabi

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Cancer is a major health concern worldwide and is still in a continuous surge of seeking for effective treatments. Since the discovery of RNAi and their mechanism of action, it has shown promises in targeted therapy for various diseases including cancer. The ability of RNAi to selectively silence the carcinogenic gene makes them ideal as cancer therapeutics. Oral delivery is the ideal route of administration of drug administration because of its patients’ compliance and convenience. However, orally administered RNAi, for instance, siRNA, must cross various extracellular and intracellular biological barriers before it reaches the site of action. It is very challenging and important to keep the siRNA stable until they reach to the targeted site. Harsh pH, thick mucus layer, and nuclease enzyme prevent siRNA to diffuse through the intestinal wall and thereby induce a therapeutic effect. After entering the cell, siRNA is subjected to lysosomal degradation. Over the years, various approaches have been taken into consideration to overcome these challenges for oral RNAi delivery. Therefore, understanding the challenges and recent development is crucial to offer a novel and advanced approach for oral RNAi delivery. Herein, we have summarized the delivery strategies for oral delivery RNAi and recent advancement towards the preclinical stages.

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391(6669), 806–811. https://doi.org/10.1038/35888CrossRefPubMed

Wang, J., & Barr, M. M. (2005). RNA interference in Caenorhabditis elegans. Methods in Enzymology, 392, 36–55. https://doi.org/10.1016/S0076-6879(04)92003-4CrossRefPubMed

Tatiparti, K., Sau, S., Kashaw, S. K., & Iyer, A. K. (2017). siRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials (Basel, Switzerland), 7(4), 77. https://doi.org/10.3390/nano7040077CrossRefPubMed

Resnier, P., Montier, T., Mathieu, V., Benoit, J.-P., & Passirani, C. (2013). A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials, 34(27), 6429–6443. https://doi.org/10.1016/j.biomaterials.2013.04.060CrossRefPubMed

Gavrilov, K., & Saltzman, W. M. (2012). Therapeutic siRNA: Principles, challenges, and strategies. Yale Journal of Biology and Medicine, 85(2), 187–200.PubMedPubMedCentral

Hammond, S. M., Caudy, A. A., & Hannon, G. J. (2001). Post-transcriptional gene silencing by double-stranded RNA. Nature Reviews Genetics, 2(2), 110–119. https://doi.org/10.1038/35052556CrossRefPubMed

Zamore, P. D., Tuschl, T., Sharp, P. A., & Bartel, D. P. (2000). RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell, 101(1), 25–33. https://doi.org/10.1016/S0092-8674(00)80620-0CrossRefPubMed

Strapps, W. R., Pickering, V., Muiru, G. T., Rice, J., Orsborn, S., Polisky, B. A., Sachs, A., & Bartz, S. R. (2010). The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing. Nucleic Acids Research, 38(14), 4788–4797. https://doi.org/10.1093/nar/gkq206CrossRefPubMedPubMedCentral

Hammond, S. M., Bernstein, E., Beach, D., & Hannon, G. J. (2000). An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature, 404(6775), 293–296. https://doi.org/10.1038/35005107CrossRefPubMed

10.

Hammond, S. M., Boettcher, S., Caudy, A. A., Kobayashi, R., & Hannon, G. J. (2001). Argonaute2, a link between genetic and biochemical analyses of RNAi. Science, 293(5532), 1146–1150. https://doi.org/10.1126/science.1064023CrossRefPubMed

11.

Oh, Y.-K., & Park, T. G. (2009). siRNA delivery systems for cancer treatment. Advanced Drug Delivery Reviews, 61(10), 850–862. https://doi.org/10.1016/j.addr.2009.04.018CrossRefPubMed

12.

Doi, N., Zenno, S., Ueda, R., Ohki-Hamazaki, H., Ui-Tei, K., & Saigo, K. (2003). Short-interfering-RNA-mediated gene silencing in mammalian cells requires dicer and eIF2C translation initiation factors. Current Biology, 13(1), 41–46. https://doi.org/10.1016/S0960-9822(02)01394-5CrossRefPubMed

13.

Afrin, H., Salazar, C. J., Kazi, M., Ahamad, S. R., Alharbi, M., & Nurunnabi, M. (2022). Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters. https://doi.org/10.1016/j.cclet.2022.01.011

14.

Huda, M. N., Deaguro, I. G., Borrego, E. A., Kumar, R., Islam, T., Afrin, H., Varela-Ramirez, A., Aguilera, R. J., Tanner, E. E. L., & Nurunnabi, M. (2022). Ionic liquid-mediated delivery of a BCL-2 inhibitor for topical treatment of skin melanoma. Journal of Controlled Release, 349, 783–795.PubMedPubMedCentralCrossRef

15.

Afrin, H., Huda, M. N., Islam, T., Oropeza, B. P., Alvidrez, E., Abir, M. I., Boland, T., Turbay, D., & Nurunnabi, M. (2022). Detection of anticancer drug-induced cardiotoxicity using VCAM1-targeted nanoprobes. ACS Applied Materials & Interfaces, 14(33), 37566–37576. https://doi.org/10.1021/acsami.2c13019CrossRef

16.

de Fougerolles, A., Vornlocher, H.-P., Maraganore, J., & Lieberman, J. (2007). Interfering with disease: A progress report on siRNA-based therapeutics. Nature Reviews Drug Discovery, 6(6), 443–453.PubMedPubMedCentralCrossRef

17.

Ye, Q.-F., Zhang, Y.-C., Peng, X.-Q., Long, Z., Ming, Y.-Z., & He, L.-Y. (2012). Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax. Oncology Letters, 3(4), 879–884.PubMedPubMedCentral

18.

Bai, Z., Zhang, Z., Qu, X., Han, W., & Ma, X. (2012). Sensitization of breast cancer cells to taxol by inhibition of taxol resistance gene 1. Oncology Letters, 3(1), 135–140.CrossRef

19.

Naghizadeh, S., Mohammadi, A., Baradaran, B., & Mansoori, B. (2019). Overcoming multiple drug resistance in lung cancer using siRNA targeted therapy. Gene, 714, 143972.PubMedCrossRef

20.

Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., & Nel, A. E. (2013). Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano, 7(2), 994–1005.PubMedPubMedCentralCrossRef

21.

Schiffelers, R. M., Ansari, A., Xu, J., Zhou, Q., Tang, Q., Storm, G., Molema, G., Lu, P. Y., Scaria, P. V., & Woodle, M. C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Research, 32(19), e149–e149.PubMedPubMedCentralCrossRef

22.

Mitragotri, S., Burke, P. A., & Langer, R. (2014). Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nature Reviews Drug Discovery, 13(9), 655–672. https://doi.org/10.1038/nrd4363CrossRefPubMedPubMedCentral

23.

Caffarel-Salvador, E., Abramson, A., Langer, R., & Traverso, G. (2017). Oral delivery of biologics using drug-device combinations. Current Opinion in Pharmacology, 36, 8–13. https://doi.org/10.1016/j.coph.2017.07.003CrossRefPubMedPubMedCentral

24.

Zelikin, A. N., Ehrhardt, C., & Healy, A. M. (2016). Materials and methods for delivery of biological drugs. Nature Chemistry, 8(11), 997–1007. https://doi.org/10.1038/nchem.2629CrossRefPubMed

25.

Morishita, M., & Peppas, N. A. (2006). Is the oral route possible for peptide and protein drug delivery? Drug Discovery Today, 11(19–20), 905–910. https://doi.org/10.1016/j.drudis.2006.08.005CrossRefPubMed

26.

Singh, A., Trivedi, P., & Jain, N. K. (2018). Advances in siRNA delivery in cancer therapy. Artificial Cells, Nanomedicine, and Biotechnology, 46(2), 274–283. https://doi.org/10.1080/21691401.2017.1307210CrossRefPubMed

27.

Kirchhoff, F. (2008). Silencing HIV-1 in vivo. Cell, 134(4), 566–568. https://doi.org/10.1016/j.cell.2008.08.004

28.

Xu, C., & Wang, J. (2015). Delivery systems for siRNA drug development in cancer therapy. Asian Journal of Pharmaceutical Sciences, 10(1), 1–12. https://doi.org/10.1016/j.ajps.2014.08.011CrossRef

29.

Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Weng, Y. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, 391(6669), 806–811. https://doi.org/10.1038/35888CrossRefPubMed

30.

Hamilton, A. J., & Baulcombe, D. C. (1999). A species of small antisense RNA in posttranscriptional gene silencing in plants. Science, 286(5441), 950–952. https://doi.org/10.1126/SCIENCE.286.5441.950/SUPPL_FILE/1042575S1_THUMB.GIFCrossRefPubMed

31.

Tuschl, T. (2001). RNA interference and small interfering RNAs. ChemBioChem, 2(4), 239–245. https://doi.org/10.1002/1439-7633(20010401)2:4%3c239::AID-CBIC239%3e3.0.CO;2-RCrossRefPubMed

32.

Eisenstein, M. (2019). Pharma’s roller-coaster relationship with RNA therapies. Nature, 574(7778), S4–S6. https://doi.org/10.1038/D41586-019-03069-3CrossRef

33.

Hu, B., Zhong, L., Weng, Y., Peng, L., Huang, Y., Zhao, Y., & Liang, X. J. (2020). Therapeutic siRNA: State of the art. Signal Transduction and Targeted Therapy, 5(1), 1–25. https://doi.org/10.1038/s41392-020-0207-xCrossRef

34.

Huang, Y. Y. (2019). Approval of the first-ever RNAi therapeutics and its technological development history. Progress in Biochemistry and Biophysics, 46, 313–322.

35.

Weng, Y. (2019). RNAi therapeutic and its innovative biotechnological evolution. Biotechnology Advances, 37, 801–825.PubMedCrossRef

36.

Blythe, R. H. (1956). Sympathomimetic preparation. Google Patents.

37.

Barenholz, Y. C. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134.PubMedCrossRef

38.

Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. Journal of Biological Chemistry, 252(11), 3582–3586.PubMedCrossRef

39.

Cordes, R. M., Sims, W. B., & Glatz, C. E. (1990). Precipitation of nucleic acids with poly (ethyleneimine). Biotechnology Progress, 6(4), 283–285. https://doi.org/10.1021/bp00004a009CrossRefPubMed

40.

Jones, D. H., Corris, S., McDonald, S., Clegg, J. C. S., & Farrar, G. H. (1997). Poly (DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine, 15(8), 814–817.PubMedCrossRef

41.

Aouadi, M., Tesz, G. J., Nicoloro, S. M., Wang, M., Chouinard, M., Soto, E., et al. (2009). Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature, 458(7242), 1180–1184. https://doi.org/10.1038/nature07774CrossRefPubMedPubMedCentral

42.

Laroui, H., Theiss, A. L., Yan, Y., Dalmasso, G., Nguyen, H. T. T., Sitaraman, S. V., & Merlin, D. (2011). Functional TNFα gene silencing mediated by polyethyleneimine/TNFα siRNA nanocomplexes in inflamed colon. Biomaterials, 32(4), 1218–1228. https://doi.org/10.1016/j.biomaterials.2010.09.062CrossRefPubMedPubMedCentral

43.

Ballarín-González, B., Dagnaes-Hansen, F., Fenton, R. A., Gao, S., Hein, S., Dong, M., & Howard, K. A. (2013). Protection and systemic translocation of siRNA following oral administration of chitosan/siRNA nanoparticles. Molecular Therapy – Nucleic Acids, 2, e76. https://doi.org/10.1038/mtna.2013.2CrossRefPubMedPubMedCentral

44.

Tahara, K., Samura, S., Tsuji, K., Yamamoto, H., Tsukada, Y., Bando, Y., Tsujimoto, H., Morishita, R., & Kawashima, Y. (2011). Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly (D, L-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials, 32(3), 870–878.PubMedCrossRef

45.

Zhang, J., Tang, C., & Yin, C. (2013). Galactosylated trimethyl chitosan–cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages. Biomaterials, 34(14), 3667–3677.PubMedCrossRef

46.

Khare, P., Dave, K. M., Kamte, Y. S., Manoharan, M. A., O’Donnell, L. A., & Manickam, D. S. (2021). Development of lipidoid nanoparticles for siRNA delivery to neural cells. The AAPS journal, 24(1), 8.PubMedCrossRef

47.

Taira, M. C., Chiaramoni, N. S., Pecuch, K. M., & Alonso-Romanowski, S. (2004). Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Delivery, 11(2), 123–128.PubMedCrossRef

48.

Miyata, K. (2021). Nucleic acid delivery across biological barriers. Yakugaku Zasshi, 141(5), 635–639. https://doi.org/10.1248/yakushi.20-00219-2CrossRefPubMed

49.

Kriegel, C., Attarwala, H., & Amiji, M. (2013). Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Advanced Drug Delivery Reviews, 65(6), 891–901. https://doi.org/10.1016/j.addr.2012.11.003CrossRefPubMed

50.

Rosenmayr-Templeton, L. (2013). The oral delivery of peptides and proteins: Established versus recently patented approaches. Pharmaceutical Patent Analyst, 2(1), 125–145. https://doi.org/10.4155/ppa.12.75CrossRefPubMed

51.

O’Driscoll, C. M., Bernkop-Schnürch, A., Friedl, J. D., Préat, V., & Jannin, V. (2019). Oral delivery of non-viral nucleic acid-based therapeutics - Do we have the guts for this? European Journal of Pharmaceutical Sciences, 133, 190–204. https://doi.org/10.1016/j.ejps.2019.03.027CrossRefPubMed

52.

Guyton, A. C., & Hall, J. E. (1986). Textbook of medical physiology. Elsevier and Saunders.

53.

Bolondi, L., Bortolotti, M., Santi, V., Calletti, T., Gaiani, S., & Labò, G. (1985). Measurement of gastric emptying time by real-time ultrasonography. Gastroenterology, 89(4), 752–759. https://doi.org/10.1016/0016-5085(85)90569-4CrossRefPubMed

54.

Ensign, L. M., Cone, R., & Hanes, J. (2012). Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Advanced drug delivery reviews, 64(6), 557–570. https://doi.org/10.1016/j.addr.2011.12.009CrossRefPubMed

55.

Kogan, A. N., & von Andrian, U. H. (2008). Microcirculation. In R. F. Tuma, W. N. Durán, & K. Ley (Eds.), Chapter 10 - Lymphocyte trafficking (2nd ed., pp. 449–482). Academic Press. https://doi.org/10.1016/B978-0-12-374530-9.00012-7CrossRef

56.

Boegh, M., & Nielsen, H. M. (2015). Mucus as a barrier to drug delivery – Understanding and mimicking the barrier properties. Basic & Clinical Pharmacology & Toxicology, 116(3), 179–186. https://doi.org/10.1111/bcpt.12342CrossRef

57.

Atuma, C., Strugala, V., Allen, A., & Holm, L. (2001). The adherent gastrointestinal mucus gel layer thickness and physical state in vivo. American Journal of Physiology-Gastrointestinal and Liver Physiology, 280(5), G922–G929.

58.

Shen, L., & Sasakawa, C. (2009). Molecular mechanisms of bacterial infection via the gut. Springer.

59.

Cone, R. A. (2009). Barrier properties of mucus. Advanced Drug Delivery Reviews, 61(2), 75–85.PubMedCrossRef

60.

Lieleg, O., & Ribbeck, K. (2011). Biological hydrogels as selective diffusion barriers. Trends in Cell Biology, 21(9), 543–551.PubMedPubMedCentralCrossRef

61.

Witten, J., & Ribbeck, K. (2017). The particle in the spider’s web: Transport through biological hydrogels. Nanoscale, 9(24), 8080–8095.PubMedPubMedCentralCrossRef

62.

Wang, Y.-Y., Schroeder, H. A., Nunn, K. L., Woods, K., Anderson, D. J., Lai, S. K., & Cone, R. A. (2016). Diffusion of immunoglobulin g in shed vaginal epithelial cells and in cell-free regions of human cervicovaginal mucus. PLoS ONE, 11(6), e0158338.PubMedPubMedCentralCrossRef

63.

Witten, J., Samad, T., & Ribbeck, K. (2018). Selective permeability of mucus barriers. Current Opinion in Biotechnology, 52, 124–133. https://doi.org/10.1016/j.copbio.2018.03.010CrossRefPubMedPubMedCentral

64.

Maturin, L., Sr., & Curtiss, R., III. (1977). Degradation of DNA by nucleases in intestinal tract of rats. Science, 196(4286), 216–218.PubMedCrossRef

65.

Hoerter, J. A. H., & Walter, N. G. (2007). Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA, 13(11), 1887–1893. https://doi.org/10.1261/rna.602307CrossRefPubMedPubMedCentral

66.

Layzer, J. M., McCaffrey, A. P., Tanner, A. K., Huang, Z., Kay, M. A., & Sullenger, B. A. (2004). In vivo activity of nuclease-resistant siRNAs. RNA, 10(5), 766–771. https://doi.org/10.1261/rna.5239604

67.

Geary, R. S., Khatsenko, O., Bunker, K., Crooke, R., Moore, M., Burckin, T., Truong, L., Sasmor, H., & Levin, A. A. (2001). Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats. Journal of Pharmacology and Experimental Therapeutics, 296(3), 898–904.PubMed

68.

Bennett, K. M., Walker, S. L., & Lo, D. D. (2014). Epithelial microvilli establish an electrostatic barrier to microbial adhesion. Infection and immunity, 82(7), 2860–2871.PubMedPubMedCentralCrossRef

69.

Goldberg, M. (2003). Gomez-Orellana I. Challenges for the oral delivery of macromolecules. Nature Reviews. Drug Discovery, 2, 289–295.PubMedCrossRef

70.

Luzio, J. P., Pryor, P. R., & Bright, N. A. (2007). Lysosomes: Fusion and function. Nature Reviews Molecular Cell Biology, 8(8), 622–632.PubMedCrossRef

71.

Maxfield, F. R., & McGraw, T. E. (2004). Endocytic recycling. Nature reviews Molecular cell biology, 5(2), 121–132.PubMedCrossRef

72.

Gu, F., Crump, C. M., & Thomas, G. (2001). Trans-Golgi network sorting. Cellular and Molecular Life Sciences CMLS, 58(8), 1067–1084.PubMedPubMedCentralCrossRef

73.

Whitehead, K. A., Langer, R., & Anderson, D. G. (2009). Knocking down barriers: Advances in siRNA delivery. Nature reviews. Drug discovery, 8(2), 129–138. https://doi.org/10.1038/nrd2742CrossRefPubMedPubMedCentral

74.

Patil, S., Gao, Y. G., Lin, X., Li, Y., Dang, K., Tian, Y., Zhang, W.-J., Jiang, S.-F., Qadir, A., & Qian, A.-R. (2019). The development of functional non-viral vectors for gene delivery. International Journal of Molecular Sciences, 20(21), 5491. https://doi.org/10.3390/ijms20215491CrossRefPubMedPubMedCentral

75.

Puhl, D. L., D’Amato, A. R., & Gilbert, R. J. (2019). Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Research Bulletin, 150, 216–230. https://doi.org/10.1016/j.brainresbull.2019.05.024CrossRefPubMedPubMedCentral

76.

Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017). Advances in the delivery of RNA therapeutics: From concept to clinical reality. Genome medicine, 9(1), 60. https://doi.org/10.1186/s13073-017-0450-0CrossRefPubMedPubMedCentral

77.

Saw, P. E., & Song, E.-W. (2020). siRNA therapeutics: A clinical reality. Science China Life Sciences, 63(4), 485–500. https://doi.org/10.1007/s11427-018-9438-yCrossRefPubMed

78.

Woodle, M. C., & Lu, P. Y. (2005). Nanoparticles deliver RNAi therapy. Materials Today, 8, 34–41.CrossRef

79.

Gupta, N., Rai, D. B., Jangid, A. K., Pooja, D., & Kulhari, H. (2019). Nanomaterials-based siRNA delivery: Routes of administration, hurdles and role of nanocarriers. In S. Singh & P. K. Maurya (Eds.), Nanotechnology in modern animal biotechnology: Recent trends and future perspectives (pp. 67–114). Springer. https://doi.org/10.1007/978-981-13-6004-6_3

80.

Eloy, J. O., Petrilli, R., Raspantini, G. L., & Lee, R. J. (2018). Targeted liposomes for siRNA delivery to cancer. Current Pharmaceutical Design, 24(23), 2664–2672.PubMedCrossRef

81.

Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013). The big picture on nanomedicine: The state of investigational and approved nanomedicine products. Nanomedicine: Nanotechnology, Biology and Medicine, 9(1), 1–14.PubMedCrossRef

82.

Allen, T. M. (1997). Liposomes. Drugs, 54(4), 8–14.PubMedCrossRef

83.

Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. International Journal of Nanomedicine, 10, 975.PubMedPubMedCentralCrossRef

84.

Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013). Delivery materials for siRNA therapeutics. Nature Materials, 12(11), 967–977.PubMedCrossRef

85.

Xia, Y., Tian, J., & Chen, X. (2016). Effect of surface properties on liposomal siRNA delivery. Biomaterials, 79, 56–68.PubMedCrossRef

86.

Wang, C., Liu, Q., Zhang, Z., Wang, Y., Zheng, Y., Hao, J., Zhao, X., Liu, Y., & Shi, L. (2021). Tumor targeted delivery of siRNA by a nano-scale quaternary polyplex for cancer treatment. Chemical Engineering Journal, 425, 130590.CrossRef

87.

Hattori, Y., Tamaki, K., Sakasai, S., Ozaki, K., & Onishi, H. (2020). Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene-silencing effects and siRNA biodistribution in mice. Molecular Medicine Reports, 22(5), 4183–4196.

88.

Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., Peng, C. G., Charisse, K., Borodovsky, A., Manoharan, M., Donahoe, J. S., Truelove, J., Nahrendorf, M., Langer, R., & Anderson, D. G. (2012). Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nature Nanotechnology, 7(6), 389–393.

89.

Shim, G., Choi, H., Lee, S., Choi, J., Yu, Y. H., Park, D.-E., Choi, Y., Kim, C.-W., & Oh, Y.-K. (2013). Enhanced intrapulmonary delivery of anticancer siRNA for lung cancer therapy using cationic ethylphosphocholine-based nanolipoplexes. Molecular Therapy, 21(4), 816–824.PubMedPubMedCentralCrossRef

90.

Ball, R. L., Knapp, C. M., & Whitehead, K. A. (2015). Lipidoid nanoparticles for siRNA delivery to the intestinal epithelium: In vitro investigations in a Caco-2 model. PLoS ONE, 10(7), e0133154.

91.

Ball, R. L., Bajaj, P., & Whitehead, K. A. (2018). Oral delivery of siRNA lipid nanoparticles: Fate in the GI tract. Scientific Reports, 8(1), 1–12.CrossRef

92.

Beuzelin, D., Pitard, B., & Kaeffer, B. (2019). Oral delivery of miRNA with lipidic aminoglycoside derivatives in the breastfed rat. Frontiers in physiology, 10, 1037.PubMedPubMedCentralCrossRef

93.

Tavares, G. A., Torres, A., Le Drean, G., Queignec, M., Castellano, B., Tesson, L., Remy, S., Anegon, I., Pitard, B., & Kaeffer, B. (2022). Oral delivery of miR-320–3p with lipidic aminoglycoside derivatives at mid-lactation alters miR-320–3p endogenous levels in the gut and brain of adult rats according to early or regular weaning. International Journal of Molecular Sciences, 24(1), 191.PubMedPubMedCentralCrossRef

94.

Chen, Q., Zhang, F., Dong, L., Wu, H., Xu, J., Li, H., Wang, J., Zhou, Z., Liu, C., Wang, Y., Liu, Y., Lu, L., Wang, C., Liu, M., Chen, X., Wang, C., Zhang, C., Li, D., Zen, K., Wang, F., Zhang, Q., & Wang, C.-Y. (2021). SIDT1-dependent absorption in the stomach mediates host uptake of dietary and orally administered microRNAs. Cell Research, 31(3), 247–258.

95.

Çetin, M., Aytekin, E., Yavuz, B., & Bozdağ-Pehlivan, S. (2017). Nanoscience in targeted brain drug delivery. In Y. Gürsoy-Özdemir, S. Bozdağ-Pehlivan, & E. Sekerdag (Eds.), Nanotechnology methods for neurological diseases and brain tumors (pp. 117–147). Elsevier.CrossRef

96.

Min, H. S., Kim, H. J., Ahn, J., Naito, M., Hayashi, K., Toh, K., Kim, B. S., Matsumura, Y., Kwon, I. C., & Miyata, K. (2018). Tuned density of anti-tissue factor antibody fragment onto siRNA-loaded polyion complex micelles for optimizing targetability into pancreatic cancer cells. Biomacromolecules, 19(6), 2320–2329.PubMedCrossRef

97.

Hazekawa, M., Nishinakagawa, T., Kawakubo-Yasukochi, T., & Nakashima, M. (2019). Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model. Journal of Pharmacological Sciences, 139(3), 231–239.PubMedCrossRef

98.

Lu, Y., Zhong, L., Jiang, Z., Pan, H., Zhang, Y., Zhu, G., Bai, L., Tong, R., Shi, J., & Duan, X. (2019). Cationic micelle-based siRNA delivery for efficient colon cancer gene therapy. Nanoscale Research Letters, 14(1), 1–9.CrossRef

99.

Cunningham, A. J., Gibson, V. P., Banquy, X., Zhu, X. X., & Jeanne, L. C. (2020). Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy. International Journal of Pharmaceutics, 578, 119078.PubMedCrossRef

100.

Muddineti, O. S., Shah, A., Rompicharla, S. V. K., Ghosh, B., & Biswas, S. (2018). Cholesterol-grafted chitosan micelles as a nanocarrier system for drug-siRNA co-delivery to the lung cancer cells. International Journal of Biological Macromolecules, 118, 857–863.PubMedCrossRef

101.

Shi, L., Feng, H., Li, Z., Shi, J., Jin, L., & Li, J. (2021). Co-delivery of paclitaxel and siRNA with pH-responsive polymeric micelles for synergistic cancer therapy. Journal of Biomedical Nanotechnology, 17(2), 322–329.PubMedCrossRef

102.

Potluri, P., & Betageri, G. V. (2006). Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. Drug Delivery, 13(3), 227–232.PubMedCrossRef

103.

Gaucher, G., Satturwar, P., Jones, M.-C., Furtos, A., & Leroux, J.-C. (2010). Polymeric micelles for oral drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 76(2), 147–158. https://doi.org/10.1016/j.ejpb.2010.06.007CrossRefPubMed

104.

Han, X., Lu, Y., Xie, J., Zhang, E., Zhu, H., Du, H., Wang, K., Song, B., Yang, C., Shi, Y., & Cao, Z. (2020). Zwitterionic micelles efficiently deliver oral insulin without opening tight junctions. Nature Nanotechnology, 15(7), 605–614. https://doi.org/10.1038/s41565-020-0693-6CrossRefPubMedPubMedCentral

105.

Ibaraki, H., Hatakeyama, N., Takeda, A., Arima, N., & Kanazawa, T. (2022). Multifunctional peptide carrier-modified polymer micelle accelerates oral siRNA-delivery to the colon and improves gene silencing-mediated therapeutic effects in ulcerative colitis. Journal of Drug Delivery Science and Technology, 73, 103481. https://doi.org/10.1016/j.jddst.2022.103481CrossRef

106.

Abbasi, E., Aval, S. F., Akbarzadeh, A., Milani, M., Nasrabadi, H. T., Joo, S. W., Hanifehpour, Y., Nejati-Koshki, K., & Pashaei-Asl, R. (2014). Dendrimers: Synthesis, applications, and properties. Nanoscale Research Letters, 9(1), 1–10.CrossRef

107.

Tambe, V., Thakkar, S., Raval, N., Sharma, D., Kalia, K., & Tekade, R. K. (2017). Surface engineered dendrimers in siRNA delivery and gene silencing. Current Pharmaceutical Design, 23(20), 2952–2975.PubMedCrossRef

108.

Michlewska, S., Ionov, M., Maroto-Díaz, M., Szwed, A., Ihnatsyeu-Kachan, A., Loznikova, S., Shcharbin, D., Maly, M., Ramirez, R. G., & de la Mata, F. J. (2018). Ruthenium dendrimers as carriers for anticancer siRNA. Journal of Inorganic Biochemistry, 181, 18–27.PubMedCrossRef

109.

Tarach, P., & Janaszewska, A. (2021). Recent advances in preclinical research using PAMAM dendrimers for cancer gene therapy. International Journal of Molecular Sciences, 22(6), 2912.PubMedPubMedCentralCrossRef

110.

Abedi-Gaballu, F., Dehghan, G., Ghaffari, M., Yekta, R., Abbaspour-Ravasjani, S., Baradaran, B., Dolatabadi, J. E. N., & Hamblin, M. R. (2018). PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Applied Materials Today, 12, 177–190.PubMedPubMedCentralCrossRef

111.

Ghaffari, M., Dehghan, G., Baradaran, B., Zarebkohan, A., Mansoori, B., Soleymani, J., & Hamblin, M. R. (2020). Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells. Colloids and Surfaces B: Biointerfaces, 188, 110762.PubMedCrossRef

112.

Ambrosio, L., Argenziano, M., Cucci, M. A., Grattarola, M., de Graaf, I. A. M., Dianzani, C., Barrera, G., Sánchez Nieves, J., Gomez, R., & Cavalli, R. (2020). Carbosilane dendrimers loaded with siRNA targeting Nrf2 as a tool to overcome cisplatin chemoresistance in bladder cancer cells. Antioxidants, 9(10), 993.PubMedPubMedCentralCrossRef

113.

Taratula, O., Garbuzenko, O., Savla, R., Andrew Wang, Y., He, H., & Minko, T. (2011). Multifunctional nanomedicine platform for cancer specific delivery of siRNA by superparamagnetic iron oxide nanoparticles-dendrimer complexes. Current Drug Delivery, 8(1), 59–69.PubMedCrossRef

114.

Liu, X., Rocchi, P., Qu, F., Zheng, S., Liang, Z., Gleave, M., Iovanna, J., & Peng, L. (2009). PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem, 4(8), 1302–1310.PubMedCrossRef

115.

Abedi Gaballu, F., Cho, W. C.-S., Dehghan, G., Zarebkohan, A., Baradaran, B., Mansoori, B., Abbaspour-Ravasjani, S., Mohammadi, A., Sheibani, N., & Aghanejad, A. (2021). Silencing of HMGA2 by siRNA loaded methotrexate functionalized polyamidoamine dendrimer for human breast cancer cell therapy. Genes, 12(7), 1102.PubMedPubMedCentralCrossRef

116.

Yellepeddi, V. K., & Ghandehari, H. (2016). Poly (amido amine) dendrimers in oral delivery. Tissue Barriers, 4(2), e1173773.PubMedPubMedCentralCrossRef

117.

Fernandes, G., Pandey, A., Kulkarni, S., Mutalik, S. P., Nikam, A. N., Seetharam, R. N., Kulkarni, S. S., & Mutalik, S. (2021). Supramolecular dendrimers based novel platforms for effective oral delivery of therapeutic moieties. Journal of Drug Delivery Science and Technology, 64, 102647. https://doi.org/10.1016/j.jddst.2021.102647CrossRef

118.

Gandhi, N. S., Godeshala, S., Koomoa-Lange, D.-L. T., Miryala, B., Rege, K., & Chougule, M. B. (2018). Bioreducible poly (amino ethers) based mTOR siRNA delivery for lung cancer. Pharmaceutical Research, 35(10), 1–20.CrossRef

119.

Hartl, N., Adams, F., Costabile, G., Isert, L., Döblinger, M., Xiao, X., Liu, R., & Merkel, O. M. (2019). The impact of Nylon-3 copolymer composition on the efficiency of siRNA delivery to glioblastoma Cells. Nanomaterials, 9(7), 986.PubMedPubMedCentralCrossRef

120.

Karlsson, J., Tzeng, S. Y., Hemmati, S., Luly, K. M., Choi, O., Rui, Y., Wilson, D. R., Kozielski, K. L., Quiñones-Hinojosa, A., & Green, J. J. (2021). Photocrosslinked bioreducible polymeric nanoparticles for enhanced systemic siRNA delivery as cancer therapy. Advanced Functional Materials, 31(17), 2009768.PubMedPubMedCentralCrossRef

121.

Yao, H., Sun, L., Li, J., Zhou, X., Li, R., Shao, R., Zhang, Y., & Li, L. (2020). A novel therapeutic siRNA nanoparticle designed for dual-targeting CD44 and Gli1 of gastric cancer stem cells. International Journal of Nanomedicine, 15, 7013.PubMedPubMedCentralCrossRef

122.

Kozielski, K. L., Ruiz-Valls, A., Tzeng, S. Y., Guerrero-Cázares, H., Rui, Y., Li, Y., Vaughan, H. J., Gionet-Gonzales, M., Vantucci, C., & Kim, J. (2019). Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo. Biomaterials, 209, 79–87.PubMedPubMedCentralCrossRef

123.

Kourani, K., Jain, P., Kumar, A., Jangid, A. K., Swaminathan, G., Durgempudi, V. R., Jose, J., Reddy, R., Pooja, D., Kulhari, H., & Kumar, L. D. (2022). Inulin coated Mn₃O₄ nanocuboids coupled with RNA interference reverse intestinal tumorigenesis in Apc knockout murine colon cancer models. Nanomedicine: Nanotechnology, Biology and Medicine, 40, 102504. https://doi.org/10.1016/j.nano.2021.102504

124.

Pędziwiatr-Werbicka, E., Gorzkiewicz, M., Michlewska, S., Ionov, M., Shcharbin, D., Klajnert-Maculewicz, B., Pena-Gonzalez, C. E., Sanchez-Nieves, J., Gomez, R., & de la Mata, F. J. (2021). Evaluation of dendronized gold nanoparticles as siRNAs carriers into cancer cells. Journal of Molecular Liquids, 324, 114726.CrossRef

125.

Yang, L., Kim, T., Cho, H., Luo, J., Lee, J., Chueng, S. D., Hou, Y., Yin, P. T., Han, J., & Kim, J. H. (2021). Hybrid graphene-gold nanoparticle-based nucleic acid conjugates for cancer-specific multimodal imaging and combined therapeutics. Advanced Functional Materials, 31(5), 2006918.PubMedCrossRef

126.

Yu, A. Y.-H., Fu, R.-H., Hsu, S., Chiu, C.-F., Fang, W.-H., Yeh, C.-A., Tang, C.-M., Hsieh, H.-H., & Hung, H.-S. (2021). Epidermal growth factor receptors siRNA-conjugated collagen modified gold nanoparticles for targeted imaging and therapy of lung cancer. Materials Today Advances, 12, 100191.CrossRef

127.

Cho, H.-J., Oh, J., Choo, M.-K., Ha, J.-I., Park, Y., & Maeng, H.-J. (2014). Chondroitin sulfate-capped gold nanoparticles for the oral delivery of insulin. International Journal of Biological Macromolecules, 63, 15–20.PubMedCrossRef

128.

Kumari, Y., Singh, S. K., Kumar, R., Kumar, B., Kaur, G., Gulati, M., Tewari, D., Gowthamarajan, K., Karri, V. V. S. N. R., & Ayinkamiye, C. (2020). Modified apple polysaccharide capped gold nanoparticles for oral delivery of insulin. International Journal of Biological Macromolecules, 149, 976–988.PubMedCrossRef

129.

Cheng, F.-F., Chen, W., Hu, L.-H., Chen, G., Miao, H.-T., Li, C., & Zhu, J.-J. (2013). Highly dispersible PEGylated graphene/Au composites as gene delivery vector and potential cancer therapeutic agent. Journal of Materials Chemistry B, 1(38), 4956–4962.PubMedCrossRef

130.

Wang, Q., Zhang, C., Shen, G., Liu, H., Fu, H., & Cui, D. (2014). Fluorescent carbon dots as an efficient siRNA nanocarrier for its interference therapy in gastric cancer cells. Journal of Nanobiotechnology. https://doi.org/10.1186/s12951-014-0058-0

131.

Sengupta, A., Mezencev, R., McDonald, J. F., & Prausnitz, M. R. (2015). Delivery of siRNA to ovarian cancer cells using laser-activated carbon nanoparticles. Nanomedicine, 10(11), 1775–1784.PubMedCrossRef

132.

Yin, F., Hu, K., Chen, Y., Yu, M., Wang, D., Wang, Q., Yong, K.-T., Lu, F., Liang, Y., & Li, Z. (2017). SiRNA delivery with PEGylated graphene oxide nanosheets for combined photothermal and genetherapy for pancreatic cancer. Theranostics, 7(5), 1133.PubMedPubMedCentralCrossRef

133.

Bae, K. H., Lee, K., Kim, C., & Park, T. G. (2011). Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials, 32(1), 176–184.PubMedCrossRef

134.

Rea, I., Martucci, N. M., De Stefano, L., Ruggiero, I., Terracciano, M., Dardano, P., Migliaccio, N., Arcari, P., Taté, R., & Rendina, I. (2014). Diatomite biosilica nanocarriers for siRNA transport inside cancer cells. Biochimica et Biophysica Acta (BBA)-General Subjects, 1840(12), 3393–3403.PubMedCrossRef

135.

Cristofolini, T., Dalmina, M., Sierra, J. A., Silva, A. H., Pasa, A. A., Pittella, F., & Creczynski-Pasa, T. B. (2020). Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells. Materials Science and Engineering: C, 109, 110555.PubMedCrossRef

136.

Mohammed, M. R. S., Ahmad, V., Ahmad, A., Tabrez, S., Choudhry, H., Zamzami, M. A., Bakhrebah, M. A., Ahmad, A., Wasi, S., & Mukhtar, H. (2021). Prospective of nanoscale metal organic frameworks [NMOFs] for cancer therapy. In Seminars in cancer biology (Vol. 69, pp. 129–139). Elsevier.

137.

Jin, L., Wang, Q., Chen, J., Wang, Z., Xin, H., & Zhang, D. (2019). Efficient delivery of therapeutic siRNA by Fe3O4 magnetic nanoparticles into oral cancer cells. Pharmaceutics, 11(11), 615. https://doi.org/10.3390/pharmaceutics11110615CrossRefPubMedPubMedCentral

138.

Keskin, D., Zu, G., Forson, A. M., Tromp, L., Sjollema, J., & van Rijn, P. (2021). Nanogels: A novel approach in antimicrobial delivery systems and antimicrobial coatings. Bioactive Materials, 6(10), 3634–3657.PubMedPubMedCentralCrossRef

139.

Spencer, D. S., Shodeinde, A. B., Beckman, D. W., Luu, B. C., Hodges, H. R., & Peppas, N. A. (2021). Cytocompatibility, membrane disruption, and siRNA delivery using environmentally responsive cationic nanogels. Journal of Controlled Release, 332, 608–619.PubMedPubMedCentralCrossRef

140.

Fujii, H., Shin-Ya, M., Takeda, S., Hashimoto, Y., Mukai, S., Sawada, S., Adachi, T., Akiyoshi, K., Miki, T., & Mazda, O. (2014). Cycloamylose-nanogel drug delivery system-mediated intratumor silencing of the vascular endothelial growth factor regulates neovascularization in tumor microenvironment. Cancer Science, 105(12), 1616–1625.PubMedPubMedCentralCrossRef

141.

Yavvari, P. S., Verma, P., Mustfa, S. A., Pal, S., Kumar, S., Awasthi, A. K., Ahuja, V., Srikanth, C. V., Srivastava, A., & Bajaj, A. (2019). A nanogel based oral gene delivery system targeting SUMOylation machinery to combat gut inflammation. Nanoscale, 11(11), 4970–4986. https://doi.org/10.1039/C8NR09599JCrossRefPubMed

142.

Knipe, J. M., Strong, L. E., & Peppas, N. A. (2016). Enzyme- and pH-responsive microencapsulated nanogels for oral delivery of siRNA to induce TNF-α knockdown in the intestine. Biomacromolecules, 17(3), 788–797. https://doi.org/10.1021/acs.biomac.5b01518CrossRefPubMed

143.

Valizadeh, A., & Mussa Farkhani, S. (2014). Electrospinning and electrospun nanofibres. IET Nanobiotechnology, 8(2), 83–92.PubMedCrossRef

144.

Lim, C. T. (2017). Nanofiber technology: Current status and emerging developments. Progress in Polymer Science, 70, 1–17.CrossRef

145.

Hu, X., Liu, S., Zhou, G., Huang, Y., Xie, Z., & Jing, X. (2014). Electrospinning of polymeric nanofibers for drug delivery applications. Journal of Controlled Release, 185, 12–21.PubMedCrossRef

146.

Chen, S., Boda, S. K., Batra, S. K., Li, X., & Xie, J. (2018). Emerging roles of electrospun nanofibers in cancer research. Advanced Healthcare Materials, 7(6), 1701024.CrossRef

147.

Stojanov, S., & Berlec, A. (2020). Electrospun nanofibers as carriers of microorganisms, stem cells, proteins, and nucleic acids in therapeutic and other applications. Frontiers in Bioengineering and Biotechnology, 8, 130.PubMedPubMedCentralCrossRef

148.

Rujitanaroj, P., Jao, B., Yang, J., Wang, F., Anderson, J. M., Wang, J., & Chew, S. Y. (2013). Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing. Acta Biomaterialia, 9(1), 4513–4524.PubMedCrossRef

149.

Pinese, C., Lin, J., Milbreta, U., Li, M., Wang, Y., Leong, K. W., & Chew, S. Y. (2018). Sustained delivery of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene silencing. Acta Biomaterialia, 76, 164–177.PubMedCrossRef

150.

Ashrafizadeh, M., Delfi, M., Hashemi, F., Zabolian, A., Saleki, H., Bagherian, M., Azami, N., Farahani, M. V., Sharifzadeh, S. O., & Hamzehlou, S. (2021). Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy. Carbohydrate Polymers, 260, 117809.PubMedCrossRef

151.

Yang, J., Dai, J., Wang, Q., Cheng, Y., Guo, J., Zhao, Z., Hong, Y., Lou, X., & Xia, F. (2020). Tumor-triggered disassembly of a multiple-agent-therapy probe for efficient cellular internalization. Angewandte Chemie, 132(46), 20585–20590.CrossRef

152.

Serrano-Sevilla, I., Artiga, Á., Mitchell, S. G., De Matteis, L., & de la Fuente, J. M. (2019). Natural polysaccharides for siRNA delivery: Nanocarriers based on chitosan, hyaluronic acid, and their derivatives. Molecules, 24(14), 2570.PubMedPubMedCentralCrossRef

153.

Choi, J. S., Han, S.-H., Hyun, C., & Yoo, H. S. (2016). Buccal adhesive nanofibers containing human growth hormone for oral mucositis. Journal of Biomedical Materials Research Part B: Applied Biomaterials, 104(7), 1396–1406. https://doi.org/10.1002/jbm.b.33487CrossRefPubMed

154.

Snook, J. D., Chesson, C. B., Peniche, A. G., Dann, S. M., Paulucci, A., Pinchuk, I. V., & Rudra, J. S. (2016). Peptide nanofiber–CaCO 3 composite microparticles as adjuvant-free oral vaccine delivery vehicles. Journal of Materials Chemistry B, 4(9), 1640–1649. https://doi.org/10.1039/C5TB01623ACrossRefPubMed

155.

Mousazadeh, H., Pilehvar-Soltanahmadi, Y., Dadashpour, M., & Zarghami, N. (2021). Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. Journal of Controlled Release, 330, 1046–1070.PubMedCrossRef

156.

Ganesh, S., Iyer, A. K., Weiler, J., Morrissey, D. V., & Amiji, M. M. (2013). Combination of siRNA-directed gene silencing with cisplatin reverses drug resistance in human non-small cell lung cancer. Molecular Therapy-Nucleic Acids, 2, e110.PubMedPubMedCentralCrossRef

157.

Eivazy, P., Atyabi, F., Jadidi-Niaragh, F., Aghebati Maleki, L., Miahipour, A., Abdolalizadeh, J., & Yousefi, M. (2017). The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). Artificial Cells, Nanomedicine, and Biotechnology, 45(5), 889–896.PubMedCrossRef

158.

Liang, Y., Wang, Y., Wang, L., Liang, Z., Li, D., Xu, X., Chen, Y., Yang, X., Zhang, H., & Niu, H. (2021). Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer. Bioactive Materials, 6(2), 433–446.PubMedCrossRef

159.

Kang, S. H., Revuri, V., Lee, S. J., Cho, S., Park, I. K., Cho, K. J., Bae, W. K., & Lee, Y. K. (2017). Oral siRNA delivery to treat colorectal liver metastases. ACS Nano. https://doi.org/10.1021/acsnano.7b05547

160.

Han, L., Tang, C., & Yin, C. (2014). Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy. Biomaterials, 35(15), 4589–4600. https://doi.org/10.1016/j.biomaterials.2014.02.027CrossRefPubMed

161.

Li, P.-P., Yan, Y., Zhang, H.-T., Cui, S., Wang, C.-H., Wei, W., Qian, H.-G., Wang, J.-C., & Zhang, Q. (2020). Biological activities of siRNA-loaded lanthanum phosphate nanoparticles on colorectal cancer. Journal of Controlled Release, 328, 45–58. https://doi.org/10.1016/j.jconrel.2020.08.027CrossRefPubMed

162.

Janardhanam, L. S. L., Bandi, S. P., & Venuganti, V. V. K. (2022). Functionalized LbL film for localized delivery of STAT3 siRNA and oxaliplatin combination to treat colon cancer. ACS Applied Materials & Interfaces, 14(8), 10030–10046. https://doi.org/10.1021/acsami.1c22166CrossRef

163.

Wei, W., Lv, P.-P., Chen, X.-M., Yue, Z.-G., Fu, Q., Liu, S.-Y., Yue, H., & Ma, G.-H. (2013). Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression. Biomaterials, 34(15), 3912–3923. https://doi.org/10.1016/j.biomaterials.2013.02.030CrossRefPubMed

164.

Shi, X.-L., Li, Y., Zhao, L.-M., Su, L.-W., & Ding, G. (2019). Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment. Colloids and Surfaces B: Biointerfaces, 173, 599–606. https://doi.org/10.1016/j.colsurfb.2018.09.076CrossRefPubMed

165.

Hyun, E.-J., Hasan, M. N., Kang, S. H., Cho, S., & Lee, Y.-K. (2019). Oral siRNA delivery using dual transporting systems to efficiently treat colorectal liver metastasis. International Journal of Pharmaceutics, 555, 250–258. https://doi.org/10.1016/j.ijpharm.2018.11.009CrossRefPubMed

166.

Zhang, L., Peng, H., Zhang, W., Li, Y., Liu, L., & Leng, T. (2020). Yeast cell wall particle mediated nanotube-RNA delivery system loaded with miR365 antagomir for post-traumatic osteoarthritis therapy via oral route. Theranostics, 10(19), 8479–8493. https://doi.org/10.7150/thno.46761CrossRefPubMedPubMedCentral

167.

Zheng, H., Tang, C., & Yin, C. (2015). Oral delivery of shRNA based on amino acid modified chitosan for improved antitumor efficacy. Biomaterials, 70, 126–137. https://doi.org/10.1016/j.biomaterials.2015.08.024CrossRefPubMed

168.

Xiang, S., Fruehauf, J., & Li, C. J. (2006). Short hairpin RNA–Expressing bacteria elicit RNA interference in mammals. Nature Biotechnology, 24(6), 697–702. https://doi.org/10.1038/nbt1211CrossRefPubMed

169.

Boddupalli, B. M., Mohammed, Z. N. K., Nath, R. A., & Banji, D. (2010). Mucoadhesive drug delivery system: An overview. Journal of Advanced Pharmaceutical Technology & Research, 1(4), 381–387. https://doi.org/10.4103/0110-5558.76436CrossRef

170.

Ahuja, A., Khar, R. K., & Ali, J. (1997). Mucoadhesive drug delivery systems. Drug Development and Industrial Pharmacy, 23(5), 489–515.CrossRef

171.

Veuillez, F., Kalia, Y. N., Jacques, Y., Deshusses, J., & Buri, P. (2001). Factors and strategies for improving buccal absorption of peptides. European journal of Pharmaceutics and Biopharmaceutics, 51(2), 93–109.PubMedCrossRef

172.

Longer, M. A., & Robinson, J. R. (1986). Fundamental-aspects of bioadhesion. Pharmacy International, 7(5), 114–117.

173.

Gu, J. M., Robinson, J. R., & Leung, S. H. (1988). Binding of acrylic polymers to mucin/epithelial surfaces: Structure-property relationships. Critical Reviews in Therapeutic Drug Carrier Systems, 5(1), 21–67.PubMed

174.

Kinloch, A. J. (1980). The science of adhesion. Journal of Materials Science, 15(9), 2141–2166.CrossRef

175.

Huntsberger, J. R. (1967). Mechanisms of adhesion. Journal Paint Technology, 39(507), 199–211.

176.

Wake, W. C. (1976). Adhesion and the formulation of adhesives. Applied Science Publishers.

177.

Kumar, R., Islam, T., & Nurunnabi, M. (2022). Mucoadhesive carriers for oral drug delivery. Journal of Controlled Release, 351, 504–559. https://doi.org/10.1016/j.jconrel.2022.09.024CrossRefPubMedPubMedCentral

178.

Yang, X., & Robinson, J. (1998). Bioadhesion in mucosal drug delivery. Academic Press.

179.

Hombach, J., & Bernkop-Schnürch, A. (2010). Mucoadhesive drug delivery systems. In M. Schäfer-Korting (Ed.), Drug delivery (pp. 251–266). Springer. https://doi.org/10.1007/978-3-642-00477-3_9CrossRef

180.

Nurunnabi, M., Afrin, H., Huda, M. N., & Salazar, C. J. J. (2023). Oral delivery compositions for obesity management. US Patent App. 17/871,953. U.S. Patent and Trademark. https://ppubs.uspto.gov/pubwebapp/static/pages/ppubsbasic.html

181.

Mao, S., Sun, W., & Kissel, T. (2010). Chitosan-based formulations for delivery of DNA and siRNA. Advanced Drug Delivery Reviews, 62(1), 12–27.PubMedCrossRef

182.

Ilium, L. (1998). Chitosan and its use as a pharmaceutical excipient. Pharmaceutical Research, 15(9), 1326–1331.CrossRef

183.

Martirosyan, A., Olesen, M. J., & Howard, K. A. (2014). Chapter Eleven - Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics. In L. Huang, D. Liu, & E. Wagner (Eds.), Nonviral vectors for gene therapy (Vol. 88, pp. 325–352). Academic Press. https://doi.org/10.1016/B978-0-12-800148-6.00011-0CrossRef

184.

Ways, M., Lau, W. M., & Khutoryanskiy, V. (2018). Chitosan and its derivatives for application in mucoadhesive drug delivery systems. Polymers, 10(3), 267. https://doi.org/10.3390/polym10030267CrossRef

185.

Hejazi, R., & Amiji, M. (2003). Chitosan-based gastrointestinal delivery systems. Journal of Controlled Release, 89(2), 151–165. https://doi.org/10.1016/S0168-3659(03)00126-3CrossRefPubMed

186.

Khutoryanskiy, V. V. (2011). Advances in mucoadhesion and mucoadhesive polymers. Macromolecular bioscience, 11(6), 748–764. https://doi.org/10.1002/mabi.201000388CrossRefPubMed

187.

Shu, X. Z., & Zhu, K. J. (2002). The influence of multivalent phosphate structure on the properties of ionically cross-linked chitosan films for controlled drug release. European Journal of Pharmaceutics and Biopharmaceutics, 54(2), 235–243.PubMedCrossRef

188.

Ballarín-González, B., & Howard, K. A. (2012). Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions. Advanced Drug Delivery Reviews, 64(15), 1717–1729. https://doi.org/10.1016/j.addr.2012.07.004CrossRefPubMed

189.

Katas, H., & Alpar, H. O. (2006). Development and characterisation of chitosan nanoparticles for siRNA delivery. Journal of Controlled Release, 115(2), 216–225.PubMedCrossRef

190.

Liu, X., Howard, K. A., Dong, M., Andersen, M. Ø., Rahbek, U. L., Johnsen, M. G., Hansen, O. C., Besenbacher, F., & Kjems, J. (2007). The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials, 28(6), 1280–1288.PubMedCrossRef

191.

Zhang, J., He, C., Tang, C., & Yin, C. (2013). Ternary polymeric nanoparticles for oral siRNA delivery. Pharmaceutical Research, 30(5), 1228–1239. https://doi.org/10.1007/s11095-012-0961-8CrossRefPubMed

192.

Roșu, M. C., Mihnea, P. D., Ardelean, A., Moldovan, S. D., Popețiu, R. O., & Totolici, B. D. (2022). Clinical significance of tumor necrosis factor-alpha and carcinoembryonic antigen in gastric cancer. Journal of Medicine and Life, 15(1), 4–6.PubMedPubMedCentralCrossRef

193.

Suganuma, M., Watanabe, T., Yamaguchi, K., Takahashi, A., & Fujiki, H. (2012). Human gastric cancer development with TNF-α-inducing protein secreted from Helicobacter pylori. Cancer letters, 322(2), 133–138. https://doi.org/10.1016/j.canlet.2012.03.027CrossRefPubMed

194.

Yu, L., Xiong, J., Guo, L., Miao, L., Liu, S., & Guo, F. (2015). The effects of lanthanum chloride on proliferation and apoptosis of cervical cancer cells: Involvement of let-7a and miR-34a microRNAs. BioMetals, 28(5), 879–890.PubMedCrossRef

195.

Su, X., Zheng, X., & Ni, J. (2009). Lanthanum citrate induces anoikis of Hela cells. Cancer Letters, 285(2), 200–209.PubMedCrossRef

196.

He, C., Yin, L., Song, Y., Tang, C., & Yin, C. (2015). Optimization of multifunctional chitosan–siRNA nanoparticles for oral delivery applications, targeting TNF-α silencing in rats. Acta Biomaterialia, 17, 98–106.PubMedCrossRef

197.

Chen, W. Y., & Abatangelo, G. (1999). Functions of hyaluronan in wound repair. Wound Repair and Regeneration: The International Journal of Tissue Repair and Regeneration, 7(2), 79–89. https://doi.org/10.1046/j.1524-475x.1999.00079.xCrossRef

198.

Fraser, J. R., Laurent, T. C., & Laurent, U. B. (1997). Hyaluronan: Its nature, distribution, functions and turnover. Journal Of Internal Medicine, 242(1), 27–33. https://doi.org/10.1046/j.1365-2796.1997.00170.xCrossRefPubMed

199.

Allison, D. D., & Grande-Allen, K. J. (2006). Review. Hyaluronan: A powerful tissue engineering tool. Tissue Engineering, 12(8), 2131–2140. https://doi.org/10.1089/ten.2006.12.2131CrossRefPubMed

200.

Griesser, J., Hetényi, G., & Bernkop-Schnürch, A. (2018). Thiolated hyaluronic acid as versatile mucoadhesive polymer: From the chemistry behind to product developments—What are the capabilities? Polymers, 10(3), 243. https://doi.org/10.3390/polym10030243CrossRefPubMedPubMedCentral

201.

Yang, J., Zhao, R., Feng, Q., Zhuo, X., & Wang, R. (2021). Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma. Investigational New Drugs, 39(1), 66–76. https://doi.org/10.1007/s10637-020-00986-3CrossRefPubMed

202.

Shahin, S. A., Wang, R., Simargi, S. I., Contreras, A., Parra Echavarria, L., Qu, L., Wen, W., Dellinger, T., Unternaehrer, J., Tamanoi, F., Zink, J. I., & Glackin, C. A. (2018). Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine: Nanotechnology, Biology and Medicine, 14(4), 1381–1394. https://doi.org/10.1016/j.nano.2018.04.008CrossRefPubMed

203.

Bastaki, S., Aravindhan, S., Ahmadpour Saheb, N., Afsari Kashani, M., Evgenievich Dorofeev, A., Karoon Kiani, F., Jahandideh, H., Beigi Dargani, F., Aksoun, M., Nikkhoo, A., Masjedi, A., Mahmoodpoor, A., Ahmadi, M., Dolati, S., Namvar Aghdash, S., & Jadidi-Niaragh, F. (2021). Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice. Life Sciences, 266, 118847. https://doi.org/10.1016/j.lfs.2020.118847CrossRefPubMed

204.

Lage, H. (2014). Chapter 5 - Bacterial delivery of RNAi effectors. In E. C. Lattime & S. L. Gerson (Eds.), Gene therapy of cancer (3rd ed., pp. 67–75). Academic Press. https://doi.org/10.1016/B978-0-12-394295-1.00005-6CrossRef

205.

D’Cruz, O., Hwang, L., Fong, A., Ng, K., Nam, D., Wang, W., & Trieu, V. (2017). Preclinical and clinical studies on safety of CEQ508 bacteria engineered to deliver short-hairpin RNA to mediate RNA interference against β-catenin in the GI tract of patients with familial adenomatous polyposis: 297. Official Journal of the American College of Gastroenterology| ACG, 112, S162–S163.CrossRef

206.

Trieu, V., Hwang, L., Ng, K., D’Cruz, O., Qazi, S., & Fong, A. (2017). First-in-human Phase I study of bacterial RNA interference therapeutic CEQ508 in patients with familial adenomatous polyposis (FAP). Annals of Oncology, 28, v174.CrossRef

207.

Zhang, L., Zhang, T., Wang, L., Shao, S., Chen, Z., & Zhang, Z. (2014). In vivo targeted delivery of CD40 shRNA to mouse intestinal dendritic cells by oral administration of recombinant Sacchromyces cerevisiae. Gene Therapy, 21(7), 709–714.

208.

Zhang, L., Zhang, W., Peng, H., Li, Y., Leng, T., Xie, C., & Zhang, L. (2021). Oral gene therapy of HFD-obesity via nonpathogenic yeast microcapsules mediated shRNA delivery. Pharmaceutics, 13(10), 1536.PubMedPubMedCentralCrossRef

209.

Zhang, L., Peng, H., Feng, M., Zhang, W., & Li, Y. (2021). Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy. Molecular Therapy-Nucleic Acids, 23, 336–346.PubMedCrossRef

210.

Islam, T., Huda, M. N., Ahsan, M. A., Afrin, H., Salazar, C. J., & Nurunnabi, M. (2021). Theoretical and experimental insights into the possible interfacial interactions between β-glucan and fat molecules in aqueous media. The Journal of Physical Chemistry B, 125(50), 13730–13743. https://doi.org/10.1021/acs.jpcb.1c08065CrossRefPubMedPubMedCentral

211.

Jeong, J. H., Mok, H., Oh, Y.-K., & Park, T. G. (2009). siRNA conjugate delivery systems. Bioconjugate Chemistry, 20(1), 5–14. https://doi.org/10.1021/bc800278eCrossRefPubMed

212.

Paredes, E., Evans, M., & Das, S. R. (2011). RNA labeling, conjugation and ligation. Methods, 54(2), 251–259. https://doi.org/10.1016/j.ymeth.2011.02.008CrossRefPubMed

213.

Lee, S. H., Kang, Y. Y., Jang, H.-E., & Mok, H. (2016). Current preclinical small interfering RNA (siRNA)-based conjugate systems for RNA therapeutics. Advanced Drug Delivery Reviews, 104, 78–92. https://doi.org/10.1016/j.addr.2015.10.009CrossRefPubMed

214.

Springer, A. D., & Dowdy, S. F. (2018). GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics, 28(3), 109–118. https://doi.org/10.1089/nat.2018.0736CrossRefPubMedPubMedCentral

215.

Yarian, F., Alibakhshi, A., Eyvazi, S., Arezumand, R., & Ahangarzadeh, S. (2019). Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy. Journal of Cellular Physiology, 234(10), 16724–16738. https://doi.org/10.1002/jcp.28490CrossRefPubMed

216.

Cuellar, T. L., Barnes, D., Nelson, C., Tanguay, J., Yu, S.-F., Wen, X., Scales, S. J., Gesch, J., Davis, D., van Brabant Smith, A., Leake, D., Vandlen, R., & Siebel, C. W. (2015). Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates. Nucleic Acids Research, 43(2), 1189–1203. https://doi.org/10.1093/nar/gku1362CrossRefPubMed

217.

Eloy, J. O., Petrilli, R., Trevizan, L. N. F., & Chorilli, M. (2017). Immunoliposomes: A review on functionalization strategies and targets for drug delivery. Colloids and Surfaces B: Biointerfaces, 159, 454–467. https://doi.org/10.1016/j.colsurfb.2017.07.085CrossRefPubMed

218.

Zhou, J., & Rossi, J. J. (2012). Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs, 26(6), 393–400. https://doi.org/10.1007/BF03261896CrossRefPubMedPubMedCentral

219.

Liao, L., Cen, B., Li, G., Wei, Y., Wang, Z., Huang, W., He, S., Yuan, Y., & Ji, A. (2021). A bivalent cyclic RGD–siRNA conjugate enhances the antitumor effect of apatinib via co-inhibiting VEGFR2 in non-small cell lung cancer xenografts. Drug Delivery, 28(1), 1432–1442. https://doi.org/10.1080/10717544.2021.1937381CrossRefPubMedPubMedCentral

220.

Kim, H. A., Nam, K., & Kim, S. W. (2014). Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials, 35(26), 7543–7552. https://doi.org/10.1016/j.biomaterials.2014.05.021CrossRefPubMedPubMedCentral

221.

Yao, Y., Sun, T., Huang, S., Dou, S., Lin, L., Chen, J., Ruan, J., Mao, C., Yu, F., Zeng, M., Zang, J., Liu, Q., Su, F., Zhang, P., Lieberman, J., Wang, J., & Song, E. (2012). Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 + breast cancer growth and metastasis. Science Translational Medicine, 4(130). https://doi.org/10.1126/scitranslmed.3003601

222.

Xu, W.-W., Liu, D., Cao, Y., & Wang, X. (2017). GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers. International Journal of Nanomedicine, 12, 6461–6470. https://doi.org/10.2147/IJN.S129946CrossRefPubMedPubMedCentral

223.

Gangopadhyay, S., Nikam, R. R., & Gore, K. R. (2021). Folate receptor-mediated siRNA delivery: Recent developments and future directions for RNAi therapeutics. Nucleic Acid Therapeutics, 31(4), 245–270. https://doi.org/10.1089/nat.2020.0882CrossRefPubMed

224.

Shim, M. S., & Kwon, Y. J. (2010). Efficient and targeted delivery of siRNA in vivo. FEBS Journal, 277(23), 4814–4827. https://doi.org/10.1111/j.1742-4658.2010.07904.x

225.

DiFiglia, M., Sena-Esteves, M., Chase, K., Sapp, E., Pfister, E., Sass, M., Yoder, J., Reeves, P., Pandey, R. K., Rajeev, K. G., Manoharan, M., Sah, D. W. Y., Zamore, P. D., & Aronin, N. (2007). Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proceedings of the National Academy of Sciences, 104(43), 17204–17209. https://doi.org/10.1073/pnas.0708285104CrossRef

226.

Dey, A. K., Griffiths, C., Lea, S. M., & James, W. (2005). Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA, 11(6), 873–884. https://doi.org/10.1261/rna.7205405CrossRefPubMedPubMedCentral

227.

Lee, J. W., Choi, J., Choi, Y., Kim, K., Yang, Y., Kim, S. H., Yoon, H. Y., & Kwon, I. C. (2022). Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy. Journal of Controlled Release, 351, 713–726. https://doi.org/10.1016/j.jconrel.2022.09.040CrossRefPubMed

228.

Research and Markets. (2022, April 21). Global RNAi therapeutics market insights & forecast report 2022–2026: Rising utilization in oncology pharmaceuticals & progress in collaborations and associated deals in RNAi therapeutics. GlobeNewswire News Room. Retrieved September 28, 2022, from https://www.globenewswire.com/en/news-release/2022/04/21/2426143/28124/en/Global-RNAi-Therapeutics-Market-Insights-Forecast-Report-2022-2026-Rising-Utilization-in-Oncology-Pharmaceuticals-Progress-in-Collaborations-and-Associated-Deals-in-RNAi-Therapeuti.html

229.

Sebastian, V. (2022). Toward continuous production of high-quality nanomaterials using microfluidics: Nanoengineering the shape, structure and chemical composition. Nanoscale, 14(12), 4411–4447. https://doi.org/10.1039/D1NR06342ACrossRefPubMed

230.

Chabattula, S. C., Gupta, P. K., Tripathi, S. K., Gahtori, R., Padhi, P., Mahapatra, S., Biswal, B. K., Singh, S. K., Dua, K., Ruokolainen, J., Mishra, Y. K., Jha, N. K., Bishi, D. K., & Kesari, K. K. (2021). Anticancer therapeutic efficacy of biogenic Am-ZnO nanoparticles on 2D and 3D tumor models. Materials Today Chemistry, 22, 100618. https://doi.org/10.1016/j.mtchem.2021.100618CrossRef

231.

Panda, S., Hajra, S., Kaushik, A., Rubahn, H. G., Mishra, Y. K., & Kim, H. J. (2022). A focused review on three-dimensional bioprinting technology for artificial organ fabrication. Biomaterials Science, 10(18), 5054–5080. https://doi.org/10.1039/D2BM00797ECrossRefPubMed

232.

Hassanzadeh, P., Atyabi, F., & Dinarvand, R. (2019). The significance of artificial intelligence in drug delivery system design. Advanced Drug Delivery Reviews, 151–152, 169–190. https://doi.org/10.1016/j.addr.2019.05.001CrossRefPubMed

233.

Gong, D., Ben-Akiva, E., Singh, A., Yamagata, H., Est-Witte, S., Shade, J. K., Trayanova, N. A., & Green, J. J. (2022). Machine learning guided structure function predictions enable in silico nanoparticle screening for polymeric gene delivery. Acta Biomaterialia, 154, 349–358.PubMedCrossRef

234.

Kearney, E., Wojcik, A., & Babu, D. (2020). Artificial intelligence in genetic services delivery: Utopia or apocalypse? Journal of Genetic Counseling, 29(1), 8–17.PubMedCrossRef

235.

Moore, J. A., & Chow, J. C. L. (2021). Recent progress and applications of gold nanotechnology in medical biophysics using artificial intelligence and mathematical modeling. Nano Express, 2(2), 22001.CrossRef

236.

Panda, S., Hajra, S., Kaushik, A., Rubahn, H. G., Mishra, Y. K., & Kim, H. J. (2022). Smart nanomaterials as the foundation of a combination approach for efficient cancer theranostics. Materials Today Chemistry, 26, 101182. https://doi.org/10.1016/j.mtchem.2022.101182CrossRef

Titel: Oral delivery of RNAi for cancer therapy
verfasst von: Humayra Afrin
Renu Geetha Bai
Raj Kumar
Sheikh Shafin Ahmad
Sandeep K. Agarwal
Md Nurunnabi
Publikationsdatum: 27.03.2023
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2023
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-023-10099-x

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Oral delivery of RNAi for cancer therapy

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Short-chain fatty acids in cancer pathogenesis

Potential biomarkers for immunotherapy in non-small-cell lung cancer

Preface

Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics

Biographies

Metabolic factors associated with the prognosis of oligometastatic patients treated with stereotactic body radiotherapy

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie